Alkermes Plc (NQ: ALKS )
22.19
USD
+0.72
(+3.35%)
Official Closing Price
Updated: 5:30 PM EST, Jan 22, 2021
Add to My Watchlist
Press releases about Alkermes Plc
Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference
May 06, 2020
From PR Newswire
Alkermes Launches COVID-19 Relief Fund to Support Innovative Programs Helping Vulnerable Patient Communities
May 04, 2020
From PR Newswire
Statement from Alkermes on Response to COVID-19
May 01, 2020
Alkermes Plc Reports First Quarter 2020 Financial Results and Provides COVID-19 Related Business Update
April 29, 2020
From PR Newswire
From PR Newswire
Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer
April 22, 2020
From PR Newswire
From PR Newswire
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 40th Annual Health Care Conference
February 24, 2020
From PR Newswire
From PR Newswire
Alkermes Plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2019 and Provides Financial Expectations for 2020
February 13, 2020
From PR Newswire
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2019 Financial Results
February 06, 2020
From PR Newswire
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
January 28, 2020
From PR Newswire
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020
From PR Newswire
Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference
November 26, 2019
From PR Newswire
Alkermes Completes Acquisition of Rodin Therapeutics
November 25, 2019
From PR Newswire
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
November 19, 2019
From PR Newswire
Alkermes to Acquire Rodin Therapeutics
November 18, 2019
From PR Newswire
From PR Newswire
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™
November 12, 2019
From PR Newswire
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
November 08, 2019
From PR Newswire
Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
November 04, 2019
From PR Newswire
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
October 30, 2019
From PR Newswire
Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring
October 23, 2019
From PR Newswire
Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
October 21, 2019
From PR Newswire
From PR Newswire
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
October 07, 2019
From PR Newswire
Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference
September 26, 2019
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.